<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Tinea Capitis (Scalp Fungal Infection) — Quick Reference Algorithm</title>
  <meta name="description" content="One‑page quick reference algorithm for diagnosis and management of tinea capitis (fungal scalp infection)." />
  <style>
    :root{
      --bg:#f7f9fc;          /* light, airy canvas */
      --card:#ffffff;         /* pure white cards */
      --ink:#1f2937;          /* slate-800 */
      --muted:#4b5563;        /* slate-600 */
      --brand:#2563eb;        /* blue-600 */
      --brand-weak:#dbeafe;   /* blue-100 */
      --ok:#059669;           /* green-600 */
      --warn:#c2410c;         /* orange-700 */
      --danger:#b91c1c;       /* red-700 */
      --hair:#94a3b8;         /* decorative */
      --ring:#e2e8f0;         /* subtle borders */
      --shadow: 0 6px 18px rgba(24,39,75,0.08);
      --radius: 16px;
      --space: 14px;
    }

    html,body{height:100%;}
    body{
      margin:0; font-family: Inter, system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji", "Segoe UI Emoji";
      color:var(--ink); background:var(--bg); line-height:1.6; 
    }

    .wrap{
      max-width: 1180px; margin: 28px auto 64px; padding: 0 20px;
    }

    header.hero{
      background: linear-gradient(180deg, #ffffff, var(--bg));
      border: 1px solid var(--ring); border-radius: var(--radius);
      box-shadow: var(--shadow); padding: 28px; position:relative; overflow:hidden;
    }

    .hero h1{ margin:0; font-size: clamp(26px, 3.2vw, 40px); letter-spacing:.2px; }
    .hero p{ margin:8px 0 0; color:var(--muted); max-width: 70ch; }

    .hero .tag{
      display:inline-block; padding:6px 10px; border-radius:999px; background:var(--brand-weak); color:var(--brand); font-weight:600; font-size:12px; letter-spacing: .3px; text-transform: uppercase; margin-bottom:10px;
    }

    .grid{
      display:grid; grid-template-columns: 300px 1fr; gap: 24px; margin-top: 24px;
    }

    @media (max-width: 960px){ .grid{ grid-template-columns: 1fr; } }

    /* Sidebar */
    .sidebar{ position: sticky; top: 20px; align-self: start; }
    .toc{ background: var(--card); border:1px solid var(--ring); border-radius: var(--radius); box-shadow: var(--shadow); padding: 16px; }
    .toc h3{ margin: 4px 0 10px; font-size: 14px; text-transform: uppercase; letter-spacing: .12em; color:var(--muted); }
    .toc a{ color: var(--ink); text-decoration:none; display:block; padding:8px 10px; border-radius:10px; }
    .toc a:hover{ background: var(--brand-weak); color: var(--brand); }

    /* Main cards */
    .section{ background:var(--card); border:1px solid var(--ring); border-radius: var(--radius); box-shadow: var(--shadow); padding: 22px; margin-bottom: 18px; }
    .section h2{ margin:0 0 6px; font-size: clamp(20px, 2.2vw, 26px); }
    .section .subtitle{ color:var(--muted); margin:0 0 14px; }

    .kicker{ font-weight:700; color:var(--brand); text-transform:uppercase; letter-spacing:.15em; font-size:12px; margin-bottom:8px; }

    .pill{ display:inline-block; padding:4px 10px; border-radius:999px; border:1px solid var(--ring); background:#fbfdff; font-size:12px; color:var(--muted); }

    .list{ margin:8px 0 0; padding-left: 18px; }
    .list li{ margin: 6px 0; }

    .two-col{ display:grid; grid-template-columns: 1fr 1fr; gap:14px; }
    @media (max-width: 720px){ .two-col{ grid-template-columns:1fr; } }

    .callout{ border-left:4px solid var(--brand); background:#fbfdff; padding:10px 12px; border-radius: 10px; }
    .callout.warn{ border-left-color: var(--warn); }
    .callout.danger{ border-left-color: var(--danger); }

    .badge{ font-weight:600; color:#0f172a; background:#eef2ff; border:1px solid #e0e7ff; padding:2px 8px; border-radius: 999px; font-size:12px; }

    .grid-3{ display:grid; grid-template-columns: repeat(3,1fr); gap:14px; }
    @media (max-width: 960px){ .grid-3{ grid-template-columns:1fr; } }

    .kv{ display:flex; align-items: baseline; gap:10px; flex-wrap: wrap; }
    .kv dt{ font-weight:600; }
    .kv dd{ margin:0; color:var(--muted); }

    .foot{ color:var(--muted); font-size:12px; margin-top:24px; }

    /* Flowchart */
    .flow{
      --c-gap: 14px; display:grid; gap: var(--c-gap);
    }
    .step{ border:1px dashed var(--ring); border-radius:12px; padding: 14px; background: #fff; }
    .step h4{ margin:0 0 6px; font-size: 16px; }
    .arrow{ text-align:center; color:#9ca3af; }

    /* Tables */
    table{ width:100%; border-collapse: collapse; }
    th, td{ text-align:left; padding:10px 8px; vertical-align: top; }
    thead th{ font-size:13px; text-transform: uppercase; letter-spacing:.12em; color:var(--muted); border-bottom:2px solid var(--ring); }
    tbody tr{ border-bottom:1px solid var(--ring); }

    /* Print */
    @media print{
      :root{ --bg:#ffffff; }
      body{ background:#fff; }
      .wrap{ max-width: 100%; margin:0; padding:0; }
      .hero, .section{ box-shadow:none; border-color:#d1d5db; }
      .sidebar{ position: static; }
      .toc{ page-break-inside: avoid; }
      .section{ page-break-inside: avoid; }
      a[href]::after{ content:" (" attr(href) ")"; font-size: 10px; color:#6b7280; }
    }
  </style>
</head>
<body>
  <div class="wrap">
    <header class="hero" role="banner">
      <span class="tag">Clinical Quick Reference · Primary Care</span>
      <h1>Tinea Capitis (Scalp Fungal Infection) — Quick Reference Algorithm</h1>
      <p>Designed for rapid decision‑making in clinic. Includes recognition, sampling, first‑line therapy, follow‑up, referral triggers, and contact management. Light theme, print‑friendly.</p>
    </header>

    <div class="grid">
      <!-- Sidebar -->
      <aside class="sidebar" aria-label="On this page">
        <nav class="toc">
          <h3>On this page</h3>
          <a href="#suspect">1. When to Suspect</a>
          <a href="#assessment">2. Assessment & Sampling</a>
          <a href="#differentials">3. Differentials</a>
          <a href="#algorithm">4. Treatment Algorithm</a>
          <a href="#pharm">5. Prescribing at a Glance</a>
          <a href="#topicals">6. Topical Adjuncts</a>
          <a href="#complications">7. Complications</a>
          <a href="#follow">8. Follow‑up & Referral</a>
          <a href="#contacts">9. Management of Contacts</a>
          <a href="#notes">Notes</a>
        </nav>
      </aside>

      <!-- Main -->
      <main>
        <section id="suspect" class="section" aria-labelledby="suspect-h">
          <div class="kicker">Recognition</div>
          <h2 id="suspect-h">1) When to suspect fungal scalp infection</h2>
          <p class="subtitle">Clinical features vary with organism, hair invasion type, and inflammatory response.</p>
          <div class="two-col">
            <div>
              <h3>Non‑inflammatory</h3>
              <ul class="list">
                <li>Diffuse scale/itch.</li>
                <li>Single/multiple <strong>asymmetrical</strong> patchy alopecia.</li>
                <li><strong>Black dots</strong> (broken hair stubs within follicles) — typical with <em>Trichophyton tonsurans</em>.</li>
              </ul>
            </div>
            <div>
              <h3>Inflammatory</h3>
              <ul class="list">
                <li>Erythema, scattered pustules, crusting.</li>
                <li>Painful boggy mass with thick crust (<strong>kerion</strong>).</li>
                <li>Post‑auricular/cervical lymphadenopathy; risk of scarring alopecia.</li>
              </ul>
            </div>
          </div>
          <div class="grid-3" style="margin-top:10px;">
            <div class="callout"><strong>Epidemiology</strong><br/>Mostly pre‑pubertal children (peak 3–7y); higher prevalence in Afro‑Caribbean children.</div>
            <div class="callout"><strong>Transmission</strong><br/>Close contact or fomites (hats, combs). Consider pets (esp. <em>Microsporum canis</em>).</div>
            <div class="callout warn"><strong>Kerion</strong><br/>Suspected kerion ⇒ <em>urgent dermatology referral</em>.</div>
          </div>
        </section>

        <section id="assessment" class="section" aria-labelledby="assessment-h">
          <div class="kicker">History · Exam · Labs</div>
          <h2 id="assessment-h">2) Assessment & Sampling</h2>
          <div class="two-col">
            <div>
              <h3>History</h3>
              <ul class="list">
                <li>Duration; itch/pain; prior OTC/antifungals.</li>
                <li>Contacts with similar scalp changes; school cohort.</li>
                <li>Animal exposure; household pets.</li>
                <li>Comorbidities incl. immunosuppression.</li>
              </ul>
              <h3>Examination</h3>
              <ul class="list">
                <li>Extent/severity, 
                  kerion?
                </li>
                <li>Eyebrows/eyelashes involved?</li>
                <li>Check for dermatophyte at other sites (nails, body, feet).</li>
              </ul>
            </div>
            <div>
              <h3>Sampling (microscopy & culture)</h3>
              <ul class="list">
                <li>Wipe off creams; scrape edge of lesions for hairs/scale with blunt scalpel.</li>
                <li>Collect ≥5&nbsp;mm² of scale/hair into folded dark paper; label well.</li>
                <li>Keep at room temp (do <em>not</em> refrigerate).</li>
                <li>Request form: treatments used, animal contacts, travel.</li>
                <li>Turnaround: microscopy 1–2 days; culture 2–3 weeks.</li>
                <li>If sampling intolerable or carrier suspected: scalp brush/cytobrush for <strong>culture</strong>.</li>
                <li>Dermoscopy can aid diagnosis/monitoring (if trained).</li>
              </ul>
            </div>
          </div>
        </section>

        <section id="differentials" class="section" aria-labelledby="diff-h">
          <div class="kicker">Rule‑outs</div>
          <h2 id="diff-h">3) Differentials</h2>
          <ul class="list">
            <li>Seborrhoeic dermatitis (greasy scale, little hair loss; face/chest involvement).</li>
            <li>Atopic eczema (itch/scale; hair loss less common).</li>
            <li>Alopecia areata (sudden discrete patches; minimal scale; “exclamation mark” hairs).</li>
            <li>Traction alopecia (marginal/temporal thinning related to hairstyles).</li>
            <li>Trichotillomania (irregular, incomplete hair loss; broken hairs of varying length; brows/lashes may be involved).</li>
            <li>Psoriasis (silver scale plaques; nails/other sites).</li>
            <li>Discoid lupus erythematosus (scaly plaques; pigment change; scarring alopecia).</li>
            <li>Lichen planus (very itchy vertex; perifollicular erythema/scale; scarring patches).</li>
            <li>Folliculitis or scalp abscess (pustules; tender collection; painful hair pluck).</li>
          </ul>
        </section>

        <section id="algorithm" class="section" aria-labelledby="algo-h">
          <div class="kicker">Action Pathway</div>
          <h2 id="algo-h">4) Treatment Algorithm (at a glance)</h2>
          <div class="flow" aria-label="Flowchart">
            <div class="step">
              <h4>Suspected tinea capitis</h4>
              <ul class="list">
                <li>Initiate self‑care / transmission reduction (see below).</li>
                <li>Take scalp scrapings/hairs for microscopy & culture.</li>
                <li><strong>Kerion?</strong> → <span class="badge">Urgent dermatology referral</span></li>
              </ul>
            </div>
            <div class="arrow">▼</div>
            <div class="step">
              <h4>Start systemic therapy (if strong suspicion or confirmed)</h4>
              <ul class="list">
                <li><strong>Adults:</strong> start oral antifungal if confirmed or highly suggestive.</li>
                <li><strong>Children:</strong> start in primary care if confident; otherwise seek paediatric derm advice.</li>
                <li><strong>Empiric choice (pending culture):</strong>
                  <ul class="list">
                    <li><em>Urban</em> (T. tonsurans likely) → <strong>Terbinafine × 4 weeks</strong>.</li>
                    <li><em>Rural</em> (Microsporum likely) → <strong>Griseofulvin × 4–8 weeks</strong>.</li>
                  </ul>
                </li>
                <li>Add <strong>ketoconazole shampoo</strong> 2–3× weekly for 2–4 weeks to reduce transmission.
                  <div class="pill">Selenium sulfide shampoo discontinued</div>
                </li>
              </ul>
            </div>
            <div class="arrow">▼</div>
            <div class="step">
              <h4>Culture result guides therapy</h4>
              <ul class="list">
                <li><strong>Trichophyton</strong> → continue/switch to <strong>terbinafine</strong>.</li>
                <li><strong>Microsporum</strong> → continue/switch to <strong>griseofulvin</strong>.</li>
                <li>If intolerance/contraindication → consider <strong>itraconazole (off‑label) × 4 weeks</strong>.</li>
              </ul>
            </div>
            <div class="arrow">▼</div>
            <div class="step">
              <h4>Review 4–8 weeks after completing oral therapy</h4>
              <ul class="list">
                <li><strong>Hair regrowth</strong> ⇒ likely clearance.</li>
                <li><strong>Persistent/recurrent signs</strong> ⇒ assess adherence, re‑exposure, interactions, immunosuppression, alternative diagnosis; <strong>repeat microscopy/culture</strong>.</li>
                <li>If improving but culture positive → consider <strong>extend treatment 2–4 weeks</strong>, then reassess.</li>
                <li>Manage complications (secondary infection, Id reaction).</li>
              </ul>
            </div>
          </div>
          <div class="callout" style="margin-top:12px;">
            <strong>School/Nursery:</strong> attend as normal once appropriate treatment is started.
          </div>
        </section>

        <section id="pharm" class="section" aria-labelledby="pharm-h">
          <div class="kicker">Dosing · Cautions · Interactions</div>
          <h2 id="pharm-h">5) Prescribing at a Glance (Systemic)</h2>

          <h3>Terbinafine (tablets only)</h3>
          <div class="two-col">
            <div>
              <table aria-label="Terbinafine dosing">
                <thead><tr><th>Age/Weight</th><th>Dose · Duration</th></tr></thead>
                <tbody>
                  <tr><td>1–17 y, 10–19 kg</td><td>62.5 mg once daily × 4 weeks</td></tr>
                  <tr><td>1–17 y, 20–39 kg</td><td>125 mg once daily × 4 weeks</td></tr>
                  <tr><td>≥40 kg or Adults</td><td>250 mg once daily × 4 weeks</td></tr>
                </tbody>
              </table>
            </div>
            <div>
              <div class="callout">
                <strong>Contraindications/Cautions</strong>
                <ul class="list">
                  <li><strong>Hepatic disease:</strong> avoid; monitor LFTs; stop if deranged.</li>
                  <li>Severe renal impairment (avoid; limited data).</li>
                  <li>Autoimmune disease (LE‑like effect), psoriasis (may worsen).</li>
                </ul>
                <strong>Key adverse effects</strong>
                <ul class="list">
                  <li>GI upset, headache; <em>taste disturbance</em>.</li>
                  <li>Rash/urticaria; rare SJS/TEN; alopecia.</li>
                  <li>Rare: hepatotoxicity, blood dyscrasias — counsel red‑flag symptoms.</li>
                </ul>
              </div>
            </div>
          </div>
          <details>
            <summary><strong>Terbinafine — notable interactions</strong></summary>
            <ul class="list">
              <li>↓ Analgesia with <em>codeine</em>.
              </li>
              <li><em>Rifampicin</em> ↓ terbinafine levels.</li>
              <li><em>Tamoxifen</em> — avoid (reduced active metabolite).</li>
              <li>↑ Levels of: flecainide/mexiletine/propafenone, SSRIs (paroxetine/sertraline), TCAs, β‑blockers, aripiprazole/risperidone, dextromethorphan, MAOI‑B (selegiline), tramadol (↑ AEs), etc.</li>
              <li>Azoles (fluconazole/ketoconazole) & amiodarone may ↑ terbinafine levels.</li>
            </ul>
          </details>

          <h3 style="margin-top:18px;">Griseofulvin</h3>
          <div class="two-col">
            <div>
              <table aria-label="Griseofulvin dosing">
                <thead><tr><th>Age</th><th>Usual Dose · Duration</th></tr></thead>
                <tbody>
                  <tr><td>1 month–11 y</td><td>10 mg/kg daily (max 500 mg); up to 20 mg/kg in severe; reduce dose when response. Once daily or divided.</td></tr>
                  <tr><td>12–17 y</td><td>500 mg daily; up to 1 g if severe; reduce when response. Once daily or divided.</td></tr>
                  <tr><td>Adults</td><td>1000 mg OD <em>or</em> 500 mg BD × 4–8 weeks</td></tr>
                </tbody>
              </table>
            </div>
            <div>
              <div class="callout">
                <strong>Contraindications/Cautions</strong>
                <ul class="list">
                  <li>Acute porphyria; severe liver disease; SLE (risk flare).</li>
                </ul>
                <strong>Key adverse effects</strong>
                <ul class="list">
                  <li>GI upset — take <strong>after high‑fat meal</strong> to ↑ absorption & ↓ AEs.</li>
                  <li>Hepatic LFT changes, cholestasis, hepatitis.</li>
                  <li>Neuro (headache, dizziness), photosensitivity, rash (incl. TEN).</li>
                  <li>May impair skilled tasks; alcohol enhances effects.</li>
                </ul>
              </div>
            </div>
          </div>
          <details>
            <summary><strong>Griseofulvin — notable interactions</strong></summary>
            <ul class="list">
              <li><strong>Alcohol:</strong> possible disulfiram‑like reaction.</li>
              <li><strong>Hormonal contraception:</strong> efficacy may be reduced — avoid COC/POP/implant/ulipristal during & 28 days after; if COC preferred, consider ≥50 µg EE with continuous/tricycling regimen + 4‑day break.</li>
              <li><strong>Warfarin:</strong> ↓ effect — monitor INR, adjust dose.</li>
              <li>Enzyme inducers (phenobarbital, primidone) ↓ griseofulvin levels.</li>
            </ul>
          </details>

          <h3 style="margin-top:18px;">Itraconazole (off‑label)</h3>
          <div class="two-col">
            <div>
              <table aria-label="Itraconazole dosing">
                <thead><tr><th>Age</th><th>Dose · Duration</th></tr></thead>
                <tbody>
                  <tr><td>1–17 y</td><td>3–5 mg/kg OD (max 200 mg) × 4 weeks</td></tr>
                  <tr><td>Adults</td><td>100 mg OD × 4 weeks</td></tr>
                </tbody>
              </table>
            </div>
            <div>
              <div class="callout warn">
                <strong>Contraindications/Cautions</strong>
                <ul class="list">
                  <li>Acute porphyria.</li>
                  <li><strong>Heart failure or ventricular dysfunction</strong> (negative inotrope).</li>
                  <li>High HF risk (e.g., CCBs), hepatic disease (monitor), renal impairment, immunocompromise.</li>
                  <li>Multiple significant <strong>CYP3A4</strong> interactions (see examples).</li>
                </ul>
                <strong>Key adverse effects</strong>
                <ul class="list">
                  <li>GI upset; rare hepatotoxicity; headache/dizziness; rash, alopecia; oedema; menstrual disorders.</li>
                </ul>
              </div>
            </div>
          </div>
          <details>
            <summary><strong>Itraconazole — notable interactions (selected)</strong></summary>
            <ul class="list">
              <li>Levels ↓ by: carbamazepine, phenytoin, phenobarbital, rifampicin/rifabutin; St John’s wort (avoid).</li>
              <li>Levels ↑ by: macrolides (clarithromycin/erythromycin), HIV protease inhibitors.</li>
              <li>Increases levels of many agents: 
                aliskiren; antipsychotics (aripiprazole, quetiapine [contraindicated], risperidone); PDE‑5 inhibitors (avoid avanafil; ↓ dose sildenafil/vardenafil); benzodiazepines (alprazolam, triazolam, midazolam); CCBs (amlodipine, verapamil); colchicine; corticosteroids (avoid budesonide/dexamethasone); digoxin (often ↓ by 50–75%); domperidone (avoid); eplerenone (contraind.); ergot alkaloids (contraind.); ivabradine (contraind.); oral anticoagulants; pimozide/quinidine/ranolazine (QT/torsades risk; generally contraind.).
              </li>
            </ul>
          </details>
        </section>

        <section id="topicals" class="section" aria-labelledby="topicals-h">
          <div class="kicker">Adjuncts</div>
          <h2 id="topicals-h">6) Topical Adjuncts (off‑label for tinea capitis)</h2>
          <div class="two-col">
            <div>
              <h3>Ketoconazole 2% shampoo</h3>
              <ul class="list">
                <li>Licensed ≥12 y (for dandruff/seb derm); use 2–3× weekly for 2–4 wks to reduce spore shedding.</li>
                <li>Avoid eye/mucosal contact. No major drug interactions reported.</li>
              </ul>
              <h3>Imidazole creams (younger children)</h3>
              <ul class="list">
                <li><strong>Clotrimazole 1%</strong> or <strong>Miconazole 2%</strong> or <strong>Econazole 1%</strong> — apply daily to affected areas (e.g., <strong>1 week</strong> for transmission reduction alongside systemic therapy).</li>
                <li>Avoid eye/mucosal contact.</li>
              </ul>
            </div>
            <div>
              <div class="callout">
                <strong>Important</strong>
                <ul class="list">
                  <li><strong>Selenium sulfide shampoo</strong> — <em>no longer available</em>.</li>
                  <li><strong>Clotrimazole ↔ tacrolimus</strong> interaction (↑ tacrolimus levels).</li>
                  <li>Miconazole/econazole topical: clinically significant anticoagulant interactions are <em>rare</em>, but consider monitoring if on oral anticoagulants.</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="two-col" style="margin-top:10px;">
            <div>
              <h3>Self‑care & Transmission Reduction</h3>
              <ul class="list">
                <li>Soften crusts (moistened dressings) then gently tease away.</li>
                <li>Discard/disinfect hats, scarves, hairbrushes, combs, pillows, blankets, scissors.</li>
                <li>Do not share towels; frequent washing.</li>
                <li>Parents/carers inspect scalps of siblings/household regularly.</li>
                <li>Suspect pet source? Arrange veterinary assessment/treatment.</li>
              </ul>
            </div>
            <div>
              <h3>School/Nursery</h3>
              <ul class="list">
                <li>Attend as normal once <strong>appropriate treatment started</strong>.</li>
              </ul>
            </div>
          </div>
        </section>

        <section id="complications" class="section" aria-labelledby="comp-h">
          <div class="kicker">Monitor & Manage</div>
          <h2 id="comp-h">7) Complications</h2>
          <ul class="list">
            <li>Secondary bacterial infection (see cellulitis/impetigo guidance).</li>
            <li><strong>Kerion</strong> → painful, boggy mass; risk scarring alopecia; <strong>urgent referral</strong>.</li>
            <li><strong>Dermatophytid (Id) reaction</strong> — pruritic papular/vesicular eruption (ears, trunk/limbs), often soon after starting oral therapy. <strong>Continue antifungal</strong>; consider topical corticosteroid for symptoms.</li>
            <li>Skin pigmentation changes; rare erythema nodosum.</li>
          </ul>
        </section>

        <section id="follow" class="section" aria-labelledby="follow-h">
          <div class="kicker">Review & Refer</div>
          <h2 id="follow-h">8) Follow‑up & Referral</h2>
          <div class="two-col">
            <div>
              <h3>Review</h3>
              <ul class="list">
                <li>Reassess <strong>4–8 weeks after completing</strong> oral therapy.</li>
                <li>Hair regrowth suggests clearance.</li>
                <li>Persistent/recurrent: check adherence, drug interactions, multiple organisms, reinfection from contacts, immunocompromise, alternative dx; repeat mycology.</li>
                <li>Ongoing improvement but positive culture: consider <strong>extend current therapy 2–4 weeks</strong>.</li>
              </ul>
            </div>
            <div>
              <h3>Refer to Dermatology</h3>
              <ul class="list">
                <li><strong>Urgent:</strong> suspected kerion.</li>
                <li>Child needs systemic therapy and primary care lacks experience.</li>
                <li>Severe/extensive or recurrent disease.</li>
                <li>Uncertain diagnosis or treatment failure.</li>
                <li>Severe Id reaction not settling in primary care.</li>
                <li>Immunocompromised host (per clinical judgement).</li>
              </ul>
            </div>
          </div>
        </section>

        <section id="contacts" class="section" aria-labelledby="contacts-h">
          <div class="kicker">Public Health</div>
          <h2 id="contacts-h">9) Management of Contacts</h2>
          <ul class="list">
            <li>Known contact of a confirmed case → arrange scalp culture (brush method acceptable) to identify infection or carriers.</li>
            <li><strong>Symptomatic + confirmed:</strong> self‑care + oral antifungal.
            </li>
            <li><strong>Asymptomatic carrier:</strong> seek dermatology advice for management/follow‑up.
              <ul class="list">
                <li><em>Heavy growth/high spore count</em> → may need oral therapy.</li>
                <li><em>Low spore load</em> → topical ketoconazole shampoo may suffice.</li>
              </ul>
            </li>
          </ul>
        </section>

        <section id="notes" class="section" aria-labelledby="notes-h">
          <div class="kicker">Notes</div>
          <h2 id="notes-h">Additional Notes</h2>
          <dl class="kv">
            <dt>Common UK organisms</dt><dd><em>T. tonsurans</em> (anthropophilic) and <em>M. canis</em> (zoophilic).</dd>
            <dt>Prognosis</dt><dd>Generally excellent with effective therapy; risk of complications without access to care or with comorbidities.</dd>
          </dl>
          <p class="foot">This quick reference is intended for clinicians as an aide‑mémoire in primary care. Consider local microbiology/dermatology pathways where applicable.</p>
        </section>
      </main>
    </div>
  </div>
</body>
</html>
